E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe sepsis or septic shock |
|
E.1.1.1 | Medical condition in easily understood language |
Svæsin sýklasótt eða sýklasóttarlost |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of HES 130/0.4 compared with a balanced crystalloid solution on mortality and endstage kidneyfailure in patients with severe sepsis |
|
E.2.2 | Secondary objectives of the trial |
To assess the effects of HES 130/0.4 compared with a balanced crystalloid solution on
· Sepsis-related organ failure assessment (SOFA, modified from (19), see Appendix 5) score (excluding Glasgow
Coma Score) at day 5 after randomisation
·Kidney failure (SOFA score > 2 in the kidney component) at any time during the ICU stay after randomisation
·Development of kidney failure (doubling of p-creatinine values) during the ICU stay after randomisation
·Development of acidosis as the lowest recorded pHa during the ICU stay after randomisation
·Need of dialysis/haemofiltration
·Need of ventilation
·Days alive without dialysis/haemofiltration
·Days alive without ventilation
·Hospital length of stay for survivors |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All adult patients who
·Undergo resuscitation in the ICU
·AND fulfilment within the previous 24 hours of the criteria for severe sepsis according to the Society of Critical
Care Medicine/American College of Chest Physicians (SCCM/ACCP), see Appendix 1
·AND consent is obtainable either from the patient or by proxy (physician and/or next of kin)
E. |
|
E.4 | Principal exclusion criteria |
·Age < 18 years
·Previously randomised in the 6S trial
·Allergy towards hydroxyethyl starch or malic acid
·Treatment with > 1000 ml’s of any synthetic colloid within the last 24 hours prior to randomisation
·Any form of renal replacement therapy
·Acute burn injury > 10% body surface area
·Severe hyperkalaemia, p-K > 6.0 mM
·Liver or kidney transplantation during current hospital admission
·Intracranial bleeding within current hospitalisation
·Enrolment into another ICU trial of drugs with potential action on circulation, renal function or coagulation
·Withdrawal of active therapy |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The composite outcome measure of 90-day mortality or end-stage kidney disease defined as dialysis-dependency
90 days after randomisation will be the primary outcome measure, and these two outcome measures will also be
analysed separately
E. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Twenty-eight-day, 6-month and 1-year mortality
• Sepsis-related organ failure assessment (SOFA, modified from (21), see Appendix 5) score (excluding Glasgow Coma Score) at day 5 after randomisation
• Kidney failure (SOFA score > 2 in the kidney component) at any time in the ICU after randomisation
• Development of kidney failure (doubling of p-creatinine values) in the ICU after randomisation
• Development of acidosis as the lowest recorded pHa in the ICU after randomisation
• Need of dialysis/haemofiltration
• Need of ventilation
• Days alive without dialysis/haemofiltration in 90 days after randomisation
• Days alive without ventilation in 90 days after randomisation
• Hospital length of stay for survivors sanctioned at 90 days after randomisation
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
28 days, 6 months and 1 year |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The independent Data Monitoring and Safety Committee - DMSC - will recommend pausing or stopping the trial
if
·Group-difference in the primary outcome measure is found at the interim analysis
·Group-difference in 30- or 90-day mortality is found at the interim analysis
·Group-difference in SUSARs or SARs is found at the interim analysis
·Results from other trials show clear benefit or harm with one of the trial fluids |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |